Stelara's Triumph At NICE May Highlight Improved Focus on Drug Value
This article was originally published in The Pink Sheet Daily
Executive Summary
A patient access scheme from Janssen has seen Stelara through the NICE process for active psoriatic arthritis, but this doesn't mean the cost watchdog is back to focusing cost.